MAIA Biotechnology, Inc. · AMEX:MAIA
MAIA Biotechnology — Investor Presentation (May 2019)
17 slides from MAIA Biotechnology's investor presentation, May 2019
Slide 1: Company Presentation
Company Presentation May 2019
Slide 2: Forward-looking Statement
Forward-looking Statement This document may be deemed to include “forward-looking statements”, including statements, other than statements of historical fact, regarding, among other things the plans for, or progress, scope, cost, duration or results or timing for availability of results of, developm
Slide 3: Who We Are and What We Do
Who We Are and What We Do Who we are: MAIA Biotechnology, Inc. is a privately-held, early stage Biotech company based in Houston TX, led by a passionate, principled and experienced Management Team. What we do: We are developing a diversified portfolio of novel mode-of-action drug candidates: 1. THIO
Slide 4: How We Do It
How We Do It • With a thoughtful business strategy designed control risk • By enhancing opportunities for success through a broad portfolio of assets • By developing compounds with novel mechanisms of action and potential activity in multiple tumor types. • MAIA combines the portfolio approach of bi
Slide 5: Projected Timelines
Projected Timelines Time to Market Compound Indication 2020 2021 2022 2023 2024 2025 2026 2027 2028 lung, melanoma, IND Clinical Development and Approvals THIO pediatric brain GMC-1 prostate, breast Lead IND Clinical Development and Approvals MJC-13 prostate, breast Lead IND Clinical Development and
Slide 6: THIO (6-thio-deoxyguanosine, 6-thio-dG)
THIO (6-thio-deoxyguanosine, 6-thio-dG) ‘Telomerase-Mediated’ and Telomere-Targeted
Slide 7: THIO is 'Telomerase-Mediated' and Telomere-Targeted
THIO is ‘Telomerase-Mediated’ and Telomere-Targeted Telomerase is present in 90% of human cancer cells. - Contributes to proliferative abilities and immortality of cancer cells. - Absent or low activity in normal cells. THIO (6-thio-dG) is recognized by 1. telomerase and incorporated into THIO telom
Slide 8: Multiple Clinical Therapeutic Failures (patient WM4265) Remain Sensitive to THIO
Multiple Clinical Therapeutic Failures (patient WM4265) Remain Sensitive to THIO • WM4265: Derived from a patient resistant to Cisplatin, Vinblastine, Temozolomide, Interleukin-2, IFN Alpha, Ipilimumab and Pembrolizumab (Checkpoint Inhibitors) 6-thio-dG 6-thio-dG 250.00 Vehicle (n=4) Control 2.5 μM
Slide 9: THIO - Summary
THIO - Summary • ~90% of all tumor types express telomerase, hTERT+ tumors can be preferentially targeted. • Telomerase activity is absent in the vast majority of normal tissues, but has increased activity in cancer cells. • THIO causes telomeric DNA damage by utilizing telomerase activity, rather t
Slide 10: GMC1 and MJC13
GMC1 and MJC13 FKBP52 Co-chaperone-Inhibitors for prostate cancer
Slide 11: FKBP52 Targeting for the Treatment of Prostate Cancer
FKBP52 Targeting for the Treatment of Prostate Cancer 11 Guy et al. Current Molecular Pharmacology (2015)
Slide 12: Evaluation of GMC in Preclinical Prostate Cancer Mouse Xenograft Models
Evaluation of GMC in Preclinical Prostate Cancer Mouse Xenograft Models 900 800 LNCaP 700 Volume(mm3) 600 CONTRO 500 L GMC1 Dose: 5mg/kg biw IT 400 300 200 100 0 0 1 2 3 4 Time( Weeks) 1000 900 CW22Rv1 800 Volumemm3 700 600 Dose: 5mg/kg biw IT CONTRO 500 400 L GMC1 300 200 100 0 0 1 2 3 4 MBT, data
Slide 13: GMC1 and MJC13 - Summary
GMC1 and MJC13 - Summary • GMC1 and MJC13 engage a new pharmacologic target, FKBP52, a cofactor required for stabilization and activity of AR – GMC binds to the co-chaperone protein FKBP52 – MJC13 binds to the AR • Binding to FKBP52 impairs AR-regulated gene expression and tumor cell growth • “Indir
Slide 14: MBT-826 (Indirubin analogue)
MBT-826 (Indirubin analogue) Selective and potent inhibitor of cyclin-dependent kinases (CDKs)
Slide 15: MBT-826 - Overview
MBT-826 - Overview • Indirubin and its derivatives are strong inhibitors of cyclin-dependent kinases (CDKs), glycogen synthase kinase-3β, c-Src kinase and STAT3 signaling, leading to cancer cell death • Indirubin is widely studied and has shown to be a very potent drug in preclinical models – Precli
Slide 16: Overall Summary
Overall Summary • Strong drug candidate pipeline across multiple Oncology indications • Strong IP position • Options for partnering with Pharma – Licensing opportunities, milestone-based partnering and/or acquisition of individual compounds MAIA Biotech develops new cancer medicines to improve and e
Slide 17: Contact Us
Contact Us http://maiabiotech.com/contact/ 17
MAIA Biotechnology — Investor Presentation (May 2019) on 6ix